Researchers find biomarker for early onset GVHD after transplant

01/8/2010 | Science News

Researchers have discovered that a protein called elafin showed up in greater concentrations among bone marrow transplant patients who exhibited a skin rash after the procedure and developed graft-versus-host disease later on compared with those who did not develop the disease. The new protein biomarker could help determine whether skin rash is a sign of early developing GVHD after bone marrow transplant, as well as identify the patients who need more aggressive treatment, the researchers said.

View Full Article in:

Science News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC